Effect of Lactobacillus brevis CD2 containing lozenges and plaque pH and cariogenic bacteria in diabetic children: a randomised clinical trial

• Objective The short-term effect (60 days) ofLactobacillus brevisCD2 lozenges vs placebo on variables related to caries and gingivitis in type 1 diabetic children was evaluated. Material and methods Eight diabetics (4-14 years old) were assigned to two groups (n= 34 subjects each), probiotic lozenges and placebo. Stimulated saliva for microbiological analysis and plaque pH were assessed at baseline (t(0)), 30 days (t(1)), 60 days (t(2)) and in the follow-up period (90 days from baseline,t(3)). Gingival status was assessed att(0),t(2)andt(3). Two-way ANOVA assessed differences between groups. Results In the probiotic group,Streptococcus mutansbacterial density mean scores dropped from 3.11 +/- 1.13 at baseline to 1.82 +/- 0.72 (t(2)) and to 2.06 +/- 0.56 (t(3)), while in the placebo group, the scores were 3.09 +/- 0.8 (t(0)), 2.82 +/- 0.47 (t(2)) and 3.11 +/- 0.43 (t(3)) (p< 0.01). Lowest and maximum pH fall increased in the probiotic group, from 5.37 +/- 0.41 at baseline to 5.49 +/- 0.24 att(3)(p< 0.01) and from 1.20 +/- 0.46 to 0.98 +/- 0.29 (p= 0.02). Bleeding score decreased significantly in both groups, showing a statistically significant lower bleeding score att(2)in the probiotic group (25.6%, 95% CI 21.5-32.7 vs 29.5%, 95% CI 25.2-34.9,p= 0.02). Conclusions Lactobacillus brevisCD2 has shown to improve caries-related risk factors and gingival health in diabetic children.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Odontologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Dentistry (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)